Y-mAbs Therapeutics Inc. (YMAB)
4.13
0.01 (0.24%)
At close: Apr 24, 2025, 3:59 PM
4.07
-1.50%
After-hours: Apr 24, 2025, 05:54 PM EDT
Y-mAbs Therapeutics Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License Revenue | 500K | 500K | 63.57M | 20.75M | 15M | n/a | 1M | n/a | n/a | 2M | n/a |
| License Revenue Growth | 0.00% | -99.21% | +206.34% | +38.34% | n/a | -100.00% | n/a | n/a | -100.00% | n/a | n/a |
| Product Revenue | 18.46M | 19.43M | n/a | n/a | 16.45M | 12.54M | 9.8M | 9.6M | 8.96M | 8.95M | 5.38M |
| Product Revenue Growth | -4.99% | n/a | n/a | n/a | +31.19% | +27.97% | +2.07% | +7.06% | +0.16% | +66.28% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 |
|---|---|
| Non-Us Revenue | 16.5M |
| Non-Us Revenue Growth | n/a |
| United States Revenue | 67.81M |
| United States Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 13.61M | 17.23M | 11.43M | 11.13M | 10.2M | 11.27M | 12.25M | 10.79M | 13.63M | 23.08M | 13.44M | 15.14M | 13.99M | 13.47M | 11.97M | 14.63M | 11.64M | 10.39M | 8.13M | 6.93M | 4.7M | 4.14M | 3.74M | 3.04M | 2.68M | 1.97M | 1.27M | 2.65M | 766K | 760.5K | 760.5K |
| Selling, General, and Administrative Revenue Growth | -21.00% | +50.83% | +2.60% | +9.17% | -9.49% | -8.01% | +13.51% | -20.79% | -40.97% | +71.77% | -11.23% | +8.22% | +3.81% | +12.57% | -18.18% | +25.73% | +11.96% | +27.91% | +17.23% | +47.50% | +13.50% | +10.64% | +23.21% | +13.15% | +36.59% | +54.12% | -51.89% | +245.95% | +0.72% | 0.00% | n/a |
| Research and Development Revenue | 11.17M | 12.34M | 13.27M | 13.39M | 15.36M | 12.05M | 13.42M | 19.79M | 22.45M | 26.42M | 22.91M | 28.76M | 23.13M | 19.78M | 21.58M | 24.01M | 21M | 30.06M | 18.62M | 16.83M | 19.66M | 14.49M | 12.51M | 11.04M | 8.73M | 8.29M | 6.2M | 6.63M | 3.08M | 2.3M | 2.3M |
| Research and Development Revenue Growth | -9.50% | -6.98% | -0.90% | -12.83% | +27.40% | -10.16% | -32.19% | -11.87% | -15.02% | +15.31% | -20.33% | +24.32% | +16.95% | -8.35% | -10.13% | +14.31% | -30.12% | +61.42% | +10.67% | -14.41% | +35.64% | +15.85% | +13.31% | +26.46% | +5.28% | +33.67% | -6.35% | +115.38% | +33.56% | 0.00% | n/a |